Weiss Ratings Reaffirms Sell (D-) Rating for Savara (NASDAQ:SVRA)

Key Points

• Weiss Ratings has restated a "sell (D-)" rating for Savara, indicating a negative outlook for the company’s stock.
• Despite the negative rating from Weiss, several research firms have given Savara an "outperform" or "buy" rating, raising target prices significantly, with a consensus target price of $7.50.
• Savara's stock performance reveals a market cap of approximately $599.75 million, with shares trading between a fifty-two week low of $1.89 and a high of $4.30.

Savara (NASDAQ:SVRA - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other research firms have also recently commented on SVRA. Oppenheimer boosted their target price on Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Guggenheim boosted their target price on Savara from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Finally, HC Wainwright boosted their target price on Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.47 on Wednesday. The stock has a market cap of $599.75 million, a PE ratio of -6.94 and a beta of 0.46. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $4.30. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock has a fifty day moving average of $3.27 and a 200-day moving average of $2.86.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Equities research analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock worth $482,000 after purchasing an additional 31,168 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Savara by 17.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company's stock worth $87,000 after purchasing an additional 5,687 shares in the last quarter. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Savara by 20.8% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock worth $48,754,000 after purchasing an additional 3,035,164 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Savara by 37.6% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,360,291 shares of the company's stock worth $3,768,000 after purchasing an additional 371,823 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Savara in the 1st quarter worth about $381,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.